{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:39:25Z","timestamp":1789756765739,"version":"4.0.1"},"reference-count":21,"publisher":"Japanese Society of Internal Medicine","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2012]]},"DOI":"10.2169\/internalmedicine.51.7049","type":"journal-article","created":{"date-parts":[[2012,6,19]],"date-time":"2012-06-19T22:43:09Z","timestamp":1340145789000},"page":"1493-1500","source":"Crossref","is-referenced-by-count":56,"title":["Intravenous Immunoglobulin (IVIg) with Methylprednisolone Pulse Therapy for Motor Impairment of Neuralgic Amyotrophy: Clinical Observations in 10 Cases"],"prefix":"10.2169","volume":"51","author":[{"given":"Ko-suke","family":"Naito","sequence":"first","affiliation":[{"name":"Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Fukushima","sequence":"additional","affiliation":[{"name":"Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiko","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Neurology, Kinki University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoi","family":"Kuwahara","sequence":"additional","affiliation":[{"name":"Department of Neurology, Kinki University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Kusunoki","sequence":"additional","affiliation":[{"name":"Department of Neurology, Kinki University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-ichi","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. MacDonald BK, Cockerell OC, Sander JW, Shorvon SD. The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. Brain: a journal of neurology 123: 665-676, 2000.","DOI":"10.1093\/brain\/123.4.665"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410180308"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. van Alfen N, van Engelen BG. The clinical spectrum of neuralgic amyotrophy in 246 cases. Brain 129: 438-450, 2006.","DOI":"10.1093\/brain\/awh722"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Collie AM, Landsverk ML, Ruzzo E, et al. Non-recurrent SEPT9 duplications cause hereditary neuralgic amyotrophy. J Med Genet 47: 601-607, 2010.","DOI":"10.1136\/jmg.2009.072348"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Magee KR, Dejong RN. Paralytic brachial neuritis. Discussion of clinical features with review of 23 cases. JAMA 174: 1258-1262, 1960.","DOI":"10.1001\/jama.1960.03030100026006"},{"key":"6","unstructured":"6. England JD, Sumner AJ. Neuralgic amyotrophy: an increasingly diverse entity. Muscle Nerve 10: 60-68, 1987."},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1046\/j.1529-8027.2002.02025.x"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1016\/0022-510X(94)90191-0"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. van Alfen N, van der Werf SP, van Engelen BG. Long-term pain, fatigue, and impairment in neuralgic amyotrophy. Arch Phys Med Rehabil 90: 435-439, 2009.","DOI":"10.1016\/j.apmr.2008.08.216"},{"key":"10","unstructured":"10. van Eijk JJ, van Alfen N, Berrevoets M, van der Wilt GJ, Pillen S, van Engelen BG. Evaluation of prednisolone treatment in the acute phase of neuralgic amyotrophy: an observational study. J Neurol Neurosurg Psychiatry 80: 1120-1124, 2009."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. van Alfen N, van Engelen BG, Hughes RA. Treatment for idiopathic and hereditary neuralgic amyotrophy (brachial neuritis). Cochrane Database Syst Rev CD006976, 2009.","DOI":"10.1002\/14651858.CD006976.pub2"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Kuhlenbaumer G, Stogbauer F, Timmerman V, De Jonghe P. Diagnostic guidelines for hereditary neuralgic amyotrophy or heredofamilial neuritis with brachial plexus predilection. On behalf of the European CMT Consortium. Neuromuscul Disord 10: 515-517, 2000.","DOI":"10.1016\/S0960-8966(00)00109-7"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Kusunoki S, Chiba A, Kon K, et al. N-acetylgalactosaminyl GD1a is a target molecule for serum antibody in Guillain-Barre syndrome. Ann Neurol 35: 570-576, 1994.","DOI":"10.1002\/ana.410350510"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Moriguchi K, Miyamoto K, Takada K, Kusunoki S. Four cases of anti-ganglioside antibody-positive neuralgic amyotrophy with good response to intravenous immunoglobulin infusion therapy. J Neuroimmunol 238: 107-109, 2011.","DOI":"10.1016\/j.jneuroim.2011.08.005"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.240550304"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Lott JA, Warren P. Estimation of reference intervals for total protein in cerebrospinal fluid. Clin Chem 35: 1766-1770, 1989.","DOI":"10.1093\/clinchem\/35.8.1766"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. van Alfen N. Clinical and pathophysiological concepts of neuralgic amyotrophy. Nat Rev Neurol 7: 315-322, 2011.","DOI":"10.1038\/nrneurol.2011.62"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Tsao BE, Avery R, Shields RW. Neuralgic amyotrophy precipitated by Epstein-Barr virus. Neurology 62: 1234-1235, 2004.","DOI":"10.1212\/01.WNL.0000118282.17433.31"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Nakajima M, Fujioka S, Ohno H, Iwamoto K. Partial but rapid recovery from paralysis after immunomodulation during early stage of neuralgic amyotrophy. Eur Neurol 55: 227-229, 2006.","DOI":"10.1159\/000093875"},{"key":"20","unstructured":"20. Al Masri O, Fathallah W, Quader S. Recovery of tacrolimus-associated brachial neuritis after conversion to everolimus in a pediatric renal transplant recipient: case report and review of the literature. Pediatr Transplant 12: 914-917, 2008."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Vriesendorp FJ, Dmytrenko GS, Dietrich T, Koski CL. Anti-peripheral nerve myelin antibodies and terminal activation products of complement in serum of patients with acute brachial plexus neuropathy. Arch Neurol 50: 1301-1303, 1993.","DOI":"10.1001\/archneur.1993.00540120016006"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/51\/12\/51_51.7049\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T17:43:21Z","timestamp":1621446201000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/51\/12\/51_51.7049\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.51.7049","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012]]}}}